SSRIs: no increased infant mortality risk

A recent study found no increased risk of stillbirth, neonatal death, or postneonatal death in infants born to women who used a selective serotonin reuptake inhibitor prescription during their pregnancies. » Full article

Low-dose aspirin for PCI

Patients with acute coronary artery syndrome and those undergoing percutaneous coronary intervention should be maintained on low-dose aspirin therapy, a recent study demonstrates. » Full article

Varenicline and cardiovascular risk

The smoking cessation aid varenicline (Chantix, Pfizer) may increase the risk of cardiovascular events in adults with cardiovascular disease, according to a recent FDA safety announcement. » Full article

Thimerosal use in vaccines

The American Academy of Pediatrics has announced its endorsement of the World Health Organization's recommendation that thimerosal not be banned from vaccines. » Full article

Comprehensive Drug Resource Helps You Save on Rx Cost: - Try Savings Calculator

Accessing all (both brand and generic) therapeutic drug alternatives provides the savings payers need, and improves member health. Learn more about how you can spend less on Rx benefits with MEDalternatives. Try cost savings calculator now.

CONTINUING EDUCATION

New CPE Series: January activity available now

Welcome to the fifth activity in our CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 credits from September 2012-March 2013 with 7 monthly knowledge-based activities. The January activity covers macrovascular and microvascular complications of diabetes mellitus.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.

Coming soon - All users will be required to provide their NABP e-Profile ID when logging into the Drug Topics' FREE CPE. This new process requires all pharmacists and pharmacy technicians to provide their NABP e-Profile ID prior to accessing the system. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

2012: A year of novel pharmacologic agents in review

In 2012, 10 newly approved or investigational drugs of interest to pharmacy and therapeutics committee members have been the subject of Formulary's "Focus on" articles. The editors have compiled the following review of these agents, along with updates on the regulatory status of each. » Full article

• SSRIs and neonatal health

• Aspirin resistance rare

• Varenicline safety review update

• MenHibrix approval

RESOURCES

Drug Watch

Latest Clinical News

SURVEY

In the midst of a major evolution in the healthcare industry, what is the most significant way in which formulary committee functions will need to evolve?

a) Greater focus on comparative effectiveness research as that data unfolds.

b) Broadened comparative review of both self-administered, as well as clinic/office-administered injectable therapies.

c) Enhanced incorporation of real-world safety and effectiveness data in review processes.

d) Modified formulary committee composition/review processes to reflect the deep pipeline of complex biologic therapies.

e) Greater demands placed upon industry to demonstrate superiority with new product introductions.

Respond here and see what your colleagues think too. Click here to see the results of our last survey.

What can Formulary do for you?

Take our super short survey TODAY! http://www.surveygizmo.com/s3/1050662/Formulary-Readers